NAD+ and Ageing: The Science Behind the Most-Hyped Longevity Molecule

In the crowded supplement market for longevity, few molecules have attracted as much serious scientific attention, and as much breathless marketing, as NAD+. Nicotinamide adenine dinucleotide is not new: it was first identified by Arthur Harden and William John Young in 1906 while studying fermentation in yeast extracts, and its structure was worked out by Hans von Euler-Chelpin in the 1930s, work that earned him a Nobel Prize. For most of the twentieth century it was understood primarily as a workhorse coenzyme in cellular metabolism, the molecule that ferries electrons from one reaction to another during glycolysis and oxidative phosphorylation. Unglamorous but essential.

What changed in the early 2000s was the discovery that NAD+ is not just a metabolic shuttle. It is also a signaling molecule with deep connections to the proteins that regulate ageing itself. When researchers at MIT demonstrated in 2000 that the lifespan-extending effects of caloric restriction in yeast required a family of proteins called sirtuins, and that sirtuins required NAD+ to function, the molecule's profile changed dramatically. Suddenly NAD+ was at the center of the most important conversation in ageing biology, and the race was on to understand why it declines with age, what that decline costs us, and whether we can do anything about it.

This article covers the real science: what NAD+ does in the cell, why levels fall as we age, what David Sinclair's lab at Harvard and other leading groups have found, how the supplement market has responded with NMN and NR, what the clinical trial data actually shows, and where the hype runs ahead of the evidence.

What NAD+ Actually Does in Your Cells

NAD+ exists in two interconvertible forms: the oxidized form (NAD+) and the reduced form (NADH). The core function people learned in biochemistry class is the redox shuttle: NAD+ accepts electrons from fuel molecules like glucose and fatty acids, becoming NADH, then passes those electrons down the mitochondrial electron transport chain to generate ATP, the cell's energy currency. This process underlies virtually all aerobic energy production, and cells with depleted NAD+ pools struggle to maintain the ATP levels needed for normal function.

But NAD+ has a second life as a substrate for a group of signaling enzymes that consume it rather than just borrowing it. Sirtuins are the most famous of these. The seven mammalian sirtuins (SIRT1 through SIRT7) are protein deacylases: they remove acetyl and other acyl groups from target proteins in reactions that require NAD+ as a co-substrate and produce nicotinamide as a byproduct. SIRT1, located primarily in the nucleus, regulates gene expression, the DNA damage response, inflammation, and circadian rhythm. SIRT3, found in the mitochondrial matrix, maintains mitochondrial function by deacetylating and activating key metabolic enzymes. When NAD+ levels fall, sirtuin activity falls proportionally, because the enzymes literally cannot catalyze their reactions without it.

The other major consumers of NAD+ in the cell are the PARP family: poly(ADP-ribose) polymerases. PARPs are the cell's emergency responders for DNA damage. When DNA strands break, PARP1 binds to the break site within seconds and uses NAD+ to build long chains of ADP-ribose polymer that signal the damage and recruit repair machinery. A cell facing significant genotoxic stress can consume enormous quantities of NAD+ through PARP activation, sometimes depleting local pools faster than biosynthetic pathways can replenish them. This creates a tug of war between the two critical NAD+-dependent systems, repair and regulation, that becomes increasingly relevant as the DNA damage load of ageing cells grows.

The Biosynthesis Routes

The body does not need to get NAD+ directly from food, because it can synthesize it through several pathways. The de novo pathway builds NAD+ from tryptophan, an amino acid found in protein-rich foods, through an eleven-step series of reactions. The Preiss-Handler pathway converts nicotinic acid (niacin, vitamin B3) to NAD+ via three enzymatic steps. And the salvage pathway, which is the dominant contributor under normal conditions, recycles nicotinamide (the byproduct released when sirtuins and PARPs cleave NAD+) back into the pool. The salvage pathway's rate-limiting step is catalyzed by an enzyme called NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide to NMN (nicotinamide mononucleotide), which is then converted to NAD+ by NMNAT enzymes. NAMPT activity declines with age, which is one of the reasons NAD+ biosynthesis slows down in older tissues.

Why NAD+ Falls With Age: Three Mechanisms

The observation that NAD+ levels decline substantially with age is well established. Studies measuring NAD+ in human blood and muscle tissue consistently find that levels at age 60 are roughly half what they were at age 20 to 30. In some tissues, the decline is even steeper. Three converging mechanisms drive this depletion, and understanding them is key to evaluating interventions.

CD38: The NAD+ Consumer That Grows With Age

The most underappreciated culprit in NAD+ decline is an enzyme called CD38, a glycohydrolase that cleaves NAD+ to produce cyclic ADP-ribose and ADP-ribose, which are calcium-mobilizing second messengers. CD38 is dramatically upregulated in ageing tissues, and a landmark 2016 paper by Eduardo Chini and colleagues at the Mayo Clinic established that CD38 activity in aged mice is elevated enough to explain the majority of the age-related NAD+ decline observed in those animals. Mice lacking the CD38 gene maintain higher NAD+ levels as they age and show improved metabolic function.

What drives CD38 upregulation in ageing? A major contributor is chronic low-grade inflammation, the smoldering inflammatory state sometimes called "inflammaging" that characterizes aged tissues. CD38 is highly expressed in immune cells, and as the immune landscape of ageing tissues shifts toward a more inflammatory composition, CD38 activity climbs with it. This creates a vicious cycle: inflammation depletes NAD+, and NAD+ depletion impairs sirtuin-mediated anti-inflammatory regulation, which allows inflammation to persist.

PARP Hyperactivation and Genotoxic Stress

Ageing cells accumulate DNA damage from decades of replication errors, oxidative stress, and environmental insults. Each episode of damage triggers PARP activation and NAD+ consumption for repair. As the total burden of DNA damage in aged cells increases, so does the chronic background activation of PARP enzymes. Research from Vilhelm Bohr's group at the National Institute on Aging, and from David Sinclair's laboratory at Harvard, has shown that interrupting this cycle, either by boosting NAD+ supply or by reducing PARP overactivation, can partially reverse several markers of cellular ageing. The implication is that PARP-mediated NAD+ drain is not just a consequence of ageing but an active driver of the deterioration in sirtuin function that follows.

Declining Biosynthetic Capacity

The third mechanism is simpler: aged cells are just less good at making NAD+. NAMPT, the rate-limiting enzyme of the salvage pathway, is expressed at lower levels in aged tissues. Tryptophan metabolism through the de novo pathway also becomes less efficient. The net result is that even without increased consumption, biosynthesis cannot keep pace with the cell's needs. Dietary restriction and exercise, two interventions with robust evidence for extending healthspan, both upregulate NAMPT expression, which may be one of the mechanisms through which they preserve metabolic vitality in ageing organisms.

David Sinclair, Sirtuins, and the Information Theory of Ageing

No researcher has done more to bring NAD+ biology to public attention than David Sinclair, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. Sinclair's lab has been at the frontier of sirtuin and NAD+ research since the late 1990s, when he was a postdoctoral fellow in Leonard Guarente's lab at MIT and contributed to the foundational papers linking Sir2 (the yeast sirtuin) to caloric restriction-mediated lifespan extension.

Sinclair has synthesized his group's findings into what he calls the Information Theory of Ageing: the idea that ageing is fundamentally a loss of epigenetic information, specifically the organized patterns of gene expression that define cell identity and function. In his framework, sirtuins are the guardians of this epigenetic information, using NAD+ to maintain chromatin structure and gene silencing patterns. When DNA damage fires PARP enzymes and drains NAD+, sirtuins are pulled away from their maintenance duties to participate in the repair response, allowing epigenetic noise to accumulate. Over decades, this noise disrupts the gene expression programs that keep cells specialized and functional.

The practical implication, according to Sinclair's work, is that restoring NAD+ levels in aged animals should partially restore sirtuin function and thereby partially reverse the epigenetic drift of ageing. His lab published a landmark 2013 paper in Cell showing that treating old mice with NMN for one week restored the muscle vasculature and exercise capacity of those mice to levels comparable to younger animals. Subsequent work showed improvements in hearing loss, eye function, and kidney health in aged mice given NAD+ precursors. These results generated enormous excitement and drove the subsequent boom in NAD+ supplement sales.

It is worth noting that this research also connects to the biology of the mitochondrial theory of ageing, where declining mitochondrial function and accumulating mitochondrial DNA damage are understood as central drivers of the ageing process. NAD+ is at the intersection of both frameworks: as a mitochondrial fuel and as an activator of SIRT3, the primary mitochondrial sirtuin.

NMN vs NR: The Supplement Debate

The realization that NAD+ declines with age and that raising it in animals reverses aspects of ageing created an obvious commercial opportunity: supplements that boost NAD+ biosynthesis. Two precursor molecules dominate the market: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are converted to NAD+ through the salvage pathway, and both have been shown in human trials to reliably elevate NAD+ levels in blood and tissues. The question is whether they differ meaningfully in bioavailability, efficacy, or clinical utility.

Charles Brenner and the Discovery of NR

NR has the longer scientific pedigree. Charles Brenner, then at Dartmouth and now at City of Hope National Medical Center, discovered in 2004 that NR is a distinct NAD+ precursor with its own dedicated salvage pathway, involving the enzymes NRK1 and NRK2 (nicotinamide riboside kinases). This discovery opened the door to NR as a dietary supplement. Brenner's group published the first human trial of NR in 2016 in Nature Communications, showing that doses of 100 to 300 mg per day raised whole-blood NAD+ in healthy adults in a dose-dependent manner, with no significant adverse effects. Subsequent trials confirmed these findings and extended them to specific populations including older adults, people with heart failure, and people with mild cognitive impairment.

NMN: One Step Closer

NMN sits one step further along the biosynthetic pathway than NR, which means it does not need to be converted to NR before being converted to NAD+. Early animal studies by Sinclair's group and by Shin-ichiro Imai's group at Washington University used NMN extensively, and those mouse results drove NMN's popularity as a supplement before substantial human trial data existed. The first major randomized controlled trial in humans, published in Science in 2021 by Imai and colleagues, enrolled healthy older men and found that 250 mg per day of NMN for ten weeks significantly increased NAD+ in blood and muscle, improved muscle insulin sensitivity, and enhanced muscle function compared to placebo.

On the question of which is better, the honest answer is that the head-to-head comparison data in humans is limited. Both compounds raise NAD+ effectively at typical supplemental doses. A key mechanistic question, whether NMN can be directly absorbed by cells via a dedicated transporter (Slc12a8, identified in mouse gut tissue in 2019), remains unresolved for human cells. From a practical standpoint, NR is generally less expensive and has a slightly larger published clinical trial database, while NMN advocates point to the mouse data's depth and to the emerging human trial evidence. Neither has been proven superior in a rigorous direct-comparison human trial.

One important consideration is that both supplements interact with the same downstream biology as mitochondrial support supplements like CoQ10. The mechanisms are complementary: CoQ10 supports electron transport chain function directly, while NAD+ precursors fuel the sirtuins that maintain mitochondrial quality. Some longevity researchers suggest combining the two may produce additive benefits, though human trial data on combination strategies is sparse.

What the Human Clinical Trials Actually Show

The past several years have seen a significant increase in the volume of human clinical trial data on NAD+ precursors, and the picture that emerges is genuinely encouraging, but more nuanced than the supplement marketing would suggest.

On the biomarker level, the data are consistent: oral NMN and NR supplementation reliably elevates NAD+ in blood and accessible tissues by 40 to 100 percent at typical doses of 250 to 500 mg per day. This is not trivial. Given that blood NAD+ is substantially lower in older adults than younger ones, restoring it to a more youthful range seems plausible and desirable. The question is what that restoration actually does to measurable health outcomes.

Several trials have reported functional improvements. A 2020 study in Nature Aging by Yoshino and colleagues found that 250 mg per day of NMN for ten weeks in postmenopausal women with prediabetes improved muscle insulin sensitivity and physical performance. A 2021 trial published in npj Aging and Mechanisms of Disease found NR supplementation (1000 mg per day for twelve weeks) modestly improved systolic blood pressure in older adults with hypertension. A phase 2 trial of NR in heart failure patients found that it raised cardiac NAD+ levels and improved markers of cardiac mitochondrial function, though it did not significantly improve clinical outcomes in the small trial.

On the safety side, both NMN and NR appear well tolerated at typical doses. The most common side effects are mild gastrointestinal symptoms that often resolve within the first week. There is ongoing discussion in the scientific community about whether high-dose NAD+ precursors could theoretically promote cancer growth in individuals with existing pre-malignant cells (since NAD+ supports both PARP-mediated DNA repair in healthy cells and energy metabolism in tumor cells), but there is no clinical evidence of increased cancer risk at the doses tested so far.

The honest limitation is that virtually all human trials to date are short-term (weeks to months), small (dozens to low hundreds of participants), and powered to detect biomarker changes rather than hard clinical endpoints like cardiovascular event rates, cognitive decline trajectories, or survival. The field is exactly where statins were in the early 1980s: the mechanism is compelling, the biomarker changes are reproducible, but the years-long outcome trials that would definitively establish clinical benefit have not been completed.

NAD+, Telomeres, and the Broader Ageing Landscape

NAD+ biology does not operate in isolation. It intersects with several other well-characterized ageing mechanisms in ways that complicate both the science and the interpretation of supplementation results.

SIRT1 has been shown to interact with the shelterin complex that protects telomere ends from inappropriate DNA repair activity. Declining SIRT1 function, driven by falling NAD+, may therefore contribute to telomere instability and the replicative senescence that accelerates with age. This connection links the NAD+ story to the biology of telomeres and telomerase in the ageing process, where the progressive shortening of chromosome caps with each cell division acts as a biological clock for cellular lifespan. The two mechanisms compound each other: short telomeres trigger DNA damage signaling that activates PARP and depletes NAD+, and depleted NAD+ impairs the SIRT1 activity needed to maintain telomere integrity.

Similarly, the senescent cells that accumulate in ageing tissues (a phenomenon called the senescence-associated secretory phenotype, or SASP) are major sources of the chronic inflammation that drives CD38 upregulation and NAD+ depletion. Senolytic therapies that clear senescent cells have been shown in mouse models to partially restore NAD+ levels in aged tissues, suggesting that targeting cellular senescence and NAD+ depletion may be synergistic strategies rather than alternatives.

Circadian rhythm disruption, which is near-universal with ageing, also ties into NAD+ biology through SIRT1's regulation of CLOCK and BMAL1, the core circadian transcription factors. When NAD+ falls and SIRT1 is less active, circadian gene expression becomes dysregulated, which in turn disrupts the rhythmic NAD+ biosynthesis that normally peaks in the early morning. This bidirectional relationship means that sleep disruption and NAD+ decline reinforce each other in a cycle that is difficult to break with supplementation alone.

Separating Signal From Hype: What We Can and Cannot Conclude

The NAD+ supplement market is worth several billion dollars annually and growing, driven by high-profile scientific advocates, compelling animal data, and consumers eager for tools to slow biological ageing. Some of the marketing claims are grounded in real science. Others substantially outrun the evidence.

What is well established: NAD+ declines substantially with age. This decline impairs the function of sirtuins, PARP-mediated DNA repair, and mitochondrial metabolism. Oral NMN and NR supplements reliably raise blood and tissue NAD+ levels in humans. Mouse studies show dramatic improvements in multiple age-related conditions when NAD+ is restored. Certain human trials show modest improvements in metabolic and physical performance markers.

What is not established: whether NAD+ supplementation extends human lifespan, whether it reduces the incidence of major age-related diseases (cardiovascular disease, cancer, neurodegeneration), and what the optimal dose, form, and duration of supplementation is for any given individual. The mouse-to-human translation problem is real: mice have a compressed lifespan, a higher metabolic rate, and very different NAD+ baseline levels compared to humans. Interventions that produce dramatic effects in mice have a poor track record of matching those effects in humans.

The honest synthesis is that NAD+ supplementation sits in the same category as many other evidence-based longevity interventions: biologically plausible, mechanistically well-supported, with encouraging early clinical data, but lacking the long-term outcome trial evidence needed to make confident clinical recommendations. For healthy adults with no specific metabolic conditions, the supplement is unlikely to harm and may provide modest benefit. For people with specific conditions where NAD+ metabolism is demonstrably impaired (certain mitochondrial diseases, obesity, type 2 diabetes), the case for supplementation is somewhat stronger. For anyone, the interventions with the most robust evidence for longevity remain unchanged: regular physical exercise, adequate sleep, caloric moderation, and not smoking. NAD+ precursors may amplify the benefits of these foundational behaviors, but they are not a substitute for them.

Tracking NAD+ Biology With the QuanMed Platform

Understanding where your own NAD+ biology stands is increasingly possible through the convergence of clinical biomarker testing and AI-driven health analysis. Blood NAD+ measurement has become available through specialized longevity clinics and direct-to-consumer testing services. Proxy biomarkers that reflect NAD+-dependent processes are even more accessible: SIRT1-regulated metabolic markers, inflammatory markers tied to CD38 activity, and mitochondrial function assessments can be obtained through standard clinical blood panels.

The challenge is interpreting these markers in the context of your individual biology, not against population averages that obscure individual variation. A 50-year-old with high-normal NAD+ and excellent mitochondrial markers has a very different risk profile, and a very different supplementation rationale, than a 50-year-old with low NAD+, elevated inflammatory markers, and poor metabolic efficiency. The QuanMed AI platform is designed to integrate exactly this kind of layered biomarker data, drawing on published research to identify where your individual trajectory sits relative to validated longevity benchmarks and flagging the specific biological systems most likely to benefit from targeted intervention.

As the NAD+ field continues to mature, with larger and longer clinical trials underway across multiple institutions, the ability to personalize NAD+-focused interventions will grow. The QuanMed platform tracks this research in real time, updating its analysis frameworks as new trial data refines the evidence base, so your understanding of your own biological ageing stays current with the science.